As of now, Aidea Pharma has 18 ongoing research projects, 15 invention patents and a cumulative total of 30 authorized patents.

The core of the 19 ongoing projects includes 8 Class 1 new drugs and 2 Class 2 new drugs. Aidea Pharma's first Class 1 innovative anti-HIV/AIDS drug, Ainuovirine Tablets, has been approved for marketing and has entered the commercialization stage, and the second Class 1 innovative anti-HIV/AIDS drug, Ainuomiti Tablets, was also approved for marketing in December 2022. As of 30 June 2023, Aidea Pharma has filed a total of 77 patent applications and has been granted a total of 29 patents, including 14 invention patents.